Clinical trials: Neoplasm, Gastrointestinal
Pancreatic Cancer
HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)
The purpuse of this study is to assess toxicities of angiogenic peptide vaccine therapy with gemcitabine in treating HLA-A*0201 restricted patient with non-resectable pancreatic cancer.
- Trial name
- NCT01266720
- Testing
- VEGFR1, VEGFR2, Gemcitabine
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Fukushima Medical University
Upper GI Cancer
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
- Trial name
- NCT02241720
- Testing
- regorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Esophageal Squamous Cell Carcinoma
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant…
- Trial name
- NCT07016724
- Testing
- cadonilizumab combined with neoadjuvant radiochemotherapy, neoadjuvant radiochemotherapy
- Where
- China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Metastatic Pancreatic Adenocarcinoma, Colorectal Cancer
TCR1020-CD8 T Cells in KRAS-mutated Cancers
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1020-CD8 T cells in patients with KRAS-mutated cancers.
- Trial name
- NCT06707896
- Testing
- TCR1020-CD8 T cells
- Sponsor
- University of Pennsylvania
Cancer of Pancreas, Cancer of the Pancreas
Epidural Analgesia Use in Pancreatic Resections
The rationale for this study is to investigate the benefits of epidural analgesia in pancreatic resections in a prospective, single blind, randomized control trial.
- Conditions
- Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer, Pancreas Neoplasms
- Trial name
- E-PRO I (NCT02681796)
- Testing
- Bupivacaine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Washington University School of Medicine
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Colitis, Ulcerative
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely…
- Trial name
- LAUREL (NCT02165215)
- Testing
- Etrolizumab
- Where
- 104 sites in United States, Brazil and 13 more
- Volunteers
- 359 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, Liver Cirrhosis
FDGal PET/CT to Detect Hepatocellular Carcinoma
Liver cancer is one of the leading causes of cancer death among Asian men. If diagnosed early the disease is treatable with surgery. Current conventional imaging modalities have limitations to early detection.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Liver Disease
- Trial name
- NCT02899325
- Testing
- Diagnostic PET/CT scans
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Pancreatic Cancer
Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00634725
- Testing
- capecitabine, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 72 sites in France
- Volunteers
- 820 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00735917
- Testing
- saracatinib, pharmacogenomic studies, pharmacological study
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)
This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in…
- Trial name
- NCT07584317
- Testing
- Artificial Intelligence
- Volunteers
- 1,170 people
- Sponsor
- Gao-jun Teng
Gastrointestinal Cancers
A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study
Hypothesis: Different patients have different biomarkers, if doctors know about the biomarkers of patients; they may be able to prescribe a regimen that is better suited to the patient's specific needs. This is a pilot study.
- Trial name
- GITIC (NCT02013089)
- Testing
- Erlotinib or Gefitinib, Everolimus, Imatinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Pancreas Cancer
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
The purpose of this research is to determine the benefit of pemigatinib in patients with advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.
- Trial name
- NCT05216120
- Testing
- Pemigatinib 4.5 MG
- Where
- United States
- Sponsor
- HonorHealth Research Institute
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Stomach Cancer, Gastric Cancer
Docetaxel and Irinotecan in Gastric Cancer
To assess the role of docetaxel and irinotecan combination in second line gastric cancer. The primary end point is response rate. Secondary end points are toxicity, PFS and OS.
- Conditions
- Stomach Cancer, Gastric Cancer, Chemotherapy Effect
- Trial name
- NCT04770623
- Testing
- Docetaxel, Irinotecan
- Where
- Egypt
- Volunteers
- 32 people
- Sponsor
- Menoufia University
Hepatocellular Carcinoma
Effect of Nutritional Indices on the Prognosis of HCC Patients
Primary liver cancer has recently ranked among the leading causes of cancer death, with hepatocellular carcinoma (HCC) accounting for 75%-85% of these cases.
- Trial name
- NCT05635279
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Juan Kang
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Neoplasm, Stomach, Neoplasm, Colorectal
Endoscopic Submucosal Dissection Registry
This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD) technique.
- Conditions
- Neoplasm, Stomach, Neoplasm, Colorectal, Neoplasm, Esophagus, Neoplasm, Duodenal
- Trial name
- ESDREG (NCT06033976)
- Testing
- Endoscopic submucosal dissection (ESD)
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Carol Davila University of Medicine and Pharmacy
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06131840
- Testing
- PF-08046050, bevacizumab, 5-Fluorouracil (5-FU)
- Where
- 48 sites in United States, Canada and 8 more
- Volunteers
- 914 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.